Jupiter Orphan Therapeutics
NASDAQ: JUNSJupiter, US · Founded 2016 · Delaware corporation
Founders & leadership
JU
Jacob UittenbogaardChief Financial Officer, Treasurer and Secretary
MH
Marshall HaywardChief Scientific Officer
CR
Christer RosenChief Executive Officer and President
CW
Claes WahlestedtConsulting Chief Medical Officer
Reported raises · per SEC filings
Form D private placements$1.4M disclosed across 3 rounds · 2016–2017
▶$100KraisedDec 2017 · 1 investors · Other Health CareRule 506(b)
▶$100KraisedDec 2017 · 1 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Marshall HaywardExecutive Officer, Director
- Christer RosenExecutive Officer, Director
- Natalie McNameeDirector
- Claes WahlestedtExecutive Officer, Director
- Jacob UittenbogaardExecutive Officer, Director
- Offering amount
- $100K
- Amount sold
- $100K
- First sale
- Nov 2017
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$1MraisedDec 2016 · 1 investors · Other Health CareRule 506(b)
▶$1MraisedDec 2016 · 1 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Natalie McNameeDirector
- Claes WahlestedtExecutive Officer, Director
- Jacob UittenbogaardExecutive Officer, Director
- Christer RosenExecutive Officer, Director
- Marshall HaywardExecutive Officer, Director
- Offering amount
- $1M
- Amount sold
- $1M
- First sale
- Dec 2016
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$250KraisedJul 2016 · 1 investors · Other Health CareRule 506(b)
▶$250KraisedJul 2016 · 1 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Jacob UittenbogaardExecutive Officer, Director
- Marshall HaywardExecutive Officer, Director
- Claes WahlestedtExecutive Officer, Director
- Christer RosenExecutive Officer, Director
- Offering amount
- $4.5M
- Amount sold
- $250K
- First sale
- Jun 2016
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2020 | $2M |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- How much funding has Jupiter Orphan Therapeutics raised?
- Jupiter Orphan Therapeutics has disclosed $1.4M raised across 3 rounds.
- Where is Jupiter Orphan Therapeutics headquartered?
- Jupiter Orphan Therapeutics is headquartered in Jupiter, US.